Amikacin

Clinical Webinar - From Theory to Practice: Maximizing Aminoglycoside Efficacy with the AUC-guided TDM

Retrieved on: 
Monday, August 28, 2023

WHAT: DoseMe, a leading provider of precision dosing software and creators of DoseMeRx and DoseMe Analytics, is hosting a free webinar on AUC-guided therapeutic drug monitoring (TDM) of aminoglycosides.

Key Points: 
  • WHAT: DoseMe, a leading provider of precision dosing software and creators of DoseMeRx and DoseMe Analytics, is hosting a free webinar on AUC-guided therapeutic drug monitoring (TDM) of aminoglycosides.
  • Featured speaker Tony Lai, Senior Pharmacist, shares his first-hand experiences implementing AUC-dosing and top tips for making your own business case.
  • New study results on how an Australian hospital improved dosing accuracy, reduced AKIs, and cut the number of labs in half in a pediatric population will also be presented.
  • Participants can expect to:
    Discover best practices for dosing and monitoring gentamycin, tobramycin and amikacin based on current and anticipated guidelines

ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, August 14, 2023

“We remain on track to file an IND for our second program, CF-370, which is our engineered lysin targeting Gram-negative pathogens, in the third quarter.

Key Points: 
  • “We remain on track to file an IND for our second program, CF-370, which is our engineered lysin targeting Gram-negative pathogens, in the third quarter.
  • Research and development (R&D) expenses were $4.9 million for the second quarter of 2023 compared to $16.8 million in the comparable period in 2022.
  • General and administrative (G&A) expenses were $3.1 million for the second quarter of 2023 compared to $3.3 million in the comparable period in 2022.
  • As of June 30, 2023, ContraFect had cash and cash equivalents of $14.4 million.

ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogens

Retrieved on: 
Tuesday, June 20, 2023

“The data presented at ASM Microbe is quite powerful.

Key Points: 
  • “The data presented at ASM Microbe is quite powerful.
  • Both dose regimens of CF-370 in addition to amikacin significantly reduced bacteria counts compared to all other treatment groups (p≤0.0001).
  • The results of this study reproduce the efficacy seen in previously released data presented at ECCMID 2023 further demonstrating the bactericidal power of CF-370 against XDR strains of Gram-negative pathogens.
  • The results of this study reinforce previously released data demonstrating the power of both CF-296 and exebacase when delivered locally in the rabbit osteomyelitis model.

ContraFect Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, May 15, 2023

The patient was treated at the Hôspices Civils de Lyon in Lyon, France, the clinical site where the study is being conducted.

Key Points: 
  • The patient was treated at the Hôspices Civils de Lyon in Lyon, France, the clinical site where the study is being conducted.
  • Research and development (R&D) expenses were $5.3 million for the first quarter of 2023 compared to $12.7 million in the comparable period in 2022.
  • General and administrative (G&A) expenses were $3.6 million for the first quarter of 2023 compared to $3.3 million in the comparable period in 2022.
  • As of March 31, 2023, ContraFect had cash, cash equivalents and marketable securities of $13.9 million.

ContraFect Data Presentations at the 33rd Annual ECCMID Meeting Highlight the Potential Efficacy of Lysin CF-370 Against Antibiotic Resistant Gram-negative Pathogens

Retrieved on: 
Thursday, April 20, 2023

“The data presented on CF-370 at ECCMID should not be understated.

Key Points: 
  • “The data presented on CF-370 at ECCMID should not be understated.
  • Amikacin alone did not demonstrate a significant reduction in bacterial density in the lungs compared to the vehicle controls (as expected for this amikacin-resistant strain).
  • However, a single dose of CF-370 alone, and in addition to amikacin, significantly reduced bacteria counts compared to vehicle controls.
  • In this in vitro study, exebacase was profiled against clinical Staphylococcus aureus (S. aureus) isolates from patients with CF.

ContraFect Announces Multiple Presentations of New Data at the 33rd Annual ECCMID Meeting

Retrieved on: 
Thursday, April 6, 2023

YONKERS, N.Y., April 06, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that the Company has been selected for an oral presentation and three poster presentations at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Annual Meeting to be held from April 15-18, 2023 in Copenhagen, Denmark. The data being presented will feature both exebacase and CF-370, the Company’s lead product candidates with CF-370 demonstrating potent in vitro bactericidal activity against drug-resistant pathogens, including multi-drug resistant (MDR) and extensively drug-resistant (XDR) strains.

Key Points: 
  • YONKERS, N.Y., April 06, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that the Company has been selected for an oral presentation and three poster presentations at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Annual Meeting to be held from April 15-18, 2023 in Copenhagen, Denmark.
  • The data being presented will feature both exebacase and CF-370, the Company’s lead product candidates with CF-370 demonstrating potent in vitro bactericidal activity against drug-resistant pathogens, including multi-drug resistant (MDR) and extensively drug-resistant (XDR) strains.
  • Title: Efficacy of lysin CF-370 in addition to amikacin in a neutropenic rabbit lung infection model caused by an extensively drug-resistant (XDR) P. aeruginosa
    Presenting Author: Mark Pulse, University of North Texas Health Science Center, College of Pharmacy

Insmed to Present New Clinical, Pre-Clinical, and Real-World Data in Serious and Rare Lung Diseases at the American Thoracic Society 2023 International Conference

Retrieved on: 
Friday, March 24, 2023

BRIDGEWATER, N.J., March 24, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that eight presentations across three of its pillars—ARIKAYCE® (amikacin liposome inhalation suspension), brensocatib, and treprostinil palmitil inhalation powder (TPIP)—will be shared at the American Thoracic Society (ATS) 2023 International Conference, taking place May 19-24, 2023, in Washington, D.C.

Key Points: 
  • BRIDGEWATER, N.J., March 24, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that eight presentations across three of its pillars—ARIKAYCE® (amikacin liposome inhalation suspension), brensocatib, and treprostinil palmitil inhalation powder (TPIP)—will be shared at the American Thoracic Society (ATS) 2023 International Conference, taking place May 19-24, 2023, in Washington, D.C.
    "We are excited to present a broad range of data from our portfolio highlighting critical topics in serious and rare lung diseases, including real-world ARIKAYCE and NTM lung disease data as well as subgroup analyses from the Phase 2 WILLOW study of brensocatib in bronchiectasis," said Martina Flammer, M.D., M.B.A, Chief Medical Officer of Insmed.
  • "We look forward to engaging with the scientific community at ATS as we work together to address the burden on patients, their providers, and the healthcare system."

Matinas BioPharma Announces Infectious Diseases Society of America (IDSA) has Selected the EnACT Phase 2 Trial Abstract of MAT2203 as its Outstanding Abstract and IDSA Awardee For IDWeek 2022

Retrieved on: 
Wednesday, October 19, 2022

Atukunda and Boulware will present the EnACT Phase 2 abstract on Friday, October 21st at the Walter E. Washington Convention Center, in Washington DC.

Key Points: 
  • Atukunda and Boulware will present the EnACT Phase 2 abstract on Friday, October 21st at the Walter E. Washington Convention Center, in Washington DC.
  • IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS) and the Society of Infectious Diseases Pharmacists (SIDP).
  • Matinas BioPharma is a biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology.
  • Matinas BioPharmas product candidates are all in a development stage and are not available for sale or use.

Matinas BioPharma to Present New MAT2203 (Oral Amphotericin B) Data During IDWeek 2022

Retrieved on: 
Wednesday, October 12, 2022

BEDMINSTER, N.J., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform delivery technology, today announced three upcoming oral data presentations during IDWeek 2022, the premier U.S. meeting of leaders in the field of infectious diseases taking place in-person at the Walter E. Washington Convention Center, in Washington DC from October 19-23, 2022.

Key Points: 
  • The data from these three presentations provide a deeper understanding of MAT2203s safety profile and impressive efficacy against two of the deadliest invasive fungal infections in cryptococcal meningitis and mucormycosis, said Theresa Matkovits, Ph.D., Chief Development Officer of Matinas BioPharma .
  • Matinas BioPharma is a biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology.
  • The Company is focused on developing an internal and external pipeline of drugs candidates based on the LNC platform.
  • Matinas BioPharmas product candidates are all in a development stage and are not available for sale or use.

Matinas BioPharma Announces Chairman Succession Plan

Retrieved on: 
Wednesday, September 21, 2022

Mr. Conrad, the founding Chairman of Matinas will remain on the Board as an independent director of the Company.

Key Points: 
  • Mr. Conrad, the founding Chairman of Matinas will remain on the Board as an independent director of the Company.
  • This change is representative of the progress we have made as a Company, commented Herbert J. Conrad, Chairman of Matinas .
  • I am honored to be appointed as the next Chairman of the Board at Matinas, stated Eric J. Ende .
  • Matinas BioPharma is a biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology.